1	1	_	_	CD	_	_	_	_	_
2	.	_	_	.	_	_	_	_	_


1	Introduction	_	_	NN	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	World	_	_	NNP	_	_	_	_	_
3	Health	_	_	NNP	_	_	_	_	_
4	Organization	_	_	NNP	_	_	_	_	_
5	(	_	_	-LRB-	_	_	_	_	_
6	WHO	_	_	NNP	_	_	_	_	_
7	)	_	_	-RRB-	_	_	_	_	_
8	classifies	_	_	VBZ	_	_	_	_	_
9	gliomas	_	_	NNS	_	_	_	_	_
10	into	_	_	IN	_	_	_	_	_
11	four	_	_	CD	_	_	_	_	_
12	categories	_	_	NNS	_	_	_	_	_
13	based	_	_	VBN	_	_	_	_	_
14	on	_	_	IN	_	_	_	_	_
15	malignancy	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	overall	_	_	JJ	_	_	_	_	_
18	survival	_	_	NN	_	_	_	_	_
19	(	_	_	-LRB-	_	_	_	_	_
20	OS	_	_	NNP	_	_	_	_	_
21	)	_	_	-RRB-	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	Glioblastoma	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	most	_	_	RBS	_	_	_	_	_
5	malignant	_	_	JJ	_	_	_	_	_
6	form	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	astrocytoma	_	_	NN	_	_	_	_	_
9	that	_	_	WDT	_	_	_	_	_
10	is	_	_	VBZ	_	_	_	_	_
11	fast-growing	_	_	JJ	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	grade	_	_	NN	_	_	_	_	_
14	4	_	_	CD	_	_	_	_	_
15	glioma	_	_	NN	_	_	_	_	_
16	)	_	_	-RRB-	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	median	_	_	JJ	_	_	_	_	_
3	OS	_	_	NN	_	_	_	_	_
4	of	_	_	IN	_	_	_	_	_
5	glioblastoma	_	_	NN	_	_	_	_	_
6	is	_	_	VBZ	_	_	_	_	_
7	9	_	_	CD	_	_	_	_	_
8	–	_	_	TO	_	_	_	_	_
9	15	_	_	CD	_	_	_	_	_
10	months	_	_	NNS	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	the	_	_	DT	_	_	_	_	_
13	five-year	_	_	JJ	_	_	_	_	_
14	survival	_	_	NN	_	_	_	_	_
15	rate	_	_	NN	_	_	_	_	_
16	remains	_	_	VBZ	_	_	_	_	_
17	less	_	_	JJR	_	_	_	_	_
18	than	_	_	IN	_	_	_	_	_
19	5	_	_	CD	_	_	_	_	_
20	%	_	_	NN	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Radiotherapy	_	_	NN	_	_	_	_	_
2	with	_	_	IN	_	_	_	_	_
3	six	_	_	CD	_	_	_	_	_
4	cycles	_	_	NNS	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	concomitant	_	_	JJ	_	_	_	_	_
7	temozolomide	_	_	NN	_	_	_	_	_
8	,	_	_	,	_	_	_	_	_
9	an	_	_	DT	_	_	_	_	_
10	oral	_	_	JJ	_	_	_	_	_
11	alkylating	_	_	JJ	_	_	_	_	_
12	agent	_	_	NN	_	_	_	_	_
13	with	_	_	IN	_	_	_	_	_
14	minimal	_	_	JJ	_	_	_	_	_
15	additional	_	_	JJ	_	_	_	_	_
16	toxicity	_	_	NN	_	_	_	_	_
17	,	_	_	,	_	_	_	_	_
18	is	_	_	VBZ	_	_	_	_	_
19	the	_	_	DT	_	_	_	_	_
20	standard	_	_	JJ	_	_	_	_	_
21	treatment	_	_	NN	_	_	_	_	_
22	after	_	_	IN	_	_	_	_	_
23	surgery	_	_	NN	_	_	_	_	_
24	in	_	_	IN	_	_	_	_	_
25	glioblastoma	_	_	NN	_	_	_	_	_
26	patients	_	_	NNS	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	Thus	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	there	_	_	EX	_	_	_	_	_
4	is	_	_	VBZ	_	_	_	_	_
5	an	_	_	DT	_	_	_	_	_
6	immediate	_	_	JJ	_	_	_	_	_
7	requirement	_	_	NN	_	_	_	_	_
8	for	_	_	IN	_	_	_	_	_
9	the	_	_	DT	_	_	_	_	_
10	early	_	_	JJ	_	_	_	_	_
11	diagnosis	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	precise	_	_	JJ	_	_	_	_	_
14	prediction	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	prognosis	_	_	NN	_	_	_	_	_
18	for	_	_	IN	_	_	_	_	_
19	treatments	_	_	NNS	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	glioblastoma	_	_	NN	_	_	_	_	_
22	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	invasiveness	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	glioblastoma	_	_	NN	_	_	_	_	_
5	depends	_	_	VBZ	_	_	_	_	_
6	on	_	_	IN	_	_	_	_	_
7	its	_	_	PRP$	_	_	_	_	_
8	high	_	_	JJ	_	_	_	_	_
9	infiltration	_	_	NN	_	_	_	_	_
10	potential	_	_	NN	_	_	_	_	_
11	to	_	_	TO	_	_	_	_	_
12	invade	_	_	VB	_	_	_	_	_
13	the	_	_	DT	_	_	_	_	_
14	basement	_	_	NN	_	_	_	_	_
15	membranes	_	_	NNS	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	surrounding	_	_	VBG	_	_	_	_	_
18	tissues	_	_	NNS	_	_	_	_	_
19	.	_	_	.	_	_	_	_	_


1	Glioma	_	_	NN	_	_	_	_	_
2	cells	_	_	NNS	_	_	_	_	_
3	are	_	_	VBP	_	_	_	_	_
4	reprogrammed	_	_	VBN	_	_	_	_	_
5	to	_	_	TO	_	_	_	_	_
6	have	_	_	VB	_	_	_	_	_
7	increased	_	_	VBN	_	_	_	_	_
8	motility	_	_	NN	_	_	_	_	_
9	via	_	_	IN	_	_	_	_	_
10	weakened	_	_	VBN	_	_	_	_	_
11	cell	_	_	NN	_	_	_	_	_
12	adhesions	_	_	NNS	_	_	_	_	_
13	and	_	_	CC	_	_	_	_	_
14	a	_	_	DT	_	_	_	_	_
15	dysregulated	_	_	JJ	_	_	_	_	_
16	cytoskeleton	_	_	NN	_	_	_	_	_
17	;	_	_	:	_	_	_	_	_
18	this	_	_	DT	_	_	_	_	_
19	is	_	_	VBZ	_	_	_	_	_
20	known	_	_	VBN	_	_	_	_	_
21	as	_	_	IN	_	_	_	_	_
22	epithelial	_	_	JJ	_	_	_	_	_
23	–	_	_	:	_	_	_	_	_
24	mesenchymal	_	_	JJ	_	_	_	_	_
25	transition	_	_	NN	_	_	_	_	_
26	(	_	_	-LRB-	_	_	_	_	_
27	EMT	_	_	NN	_	_	_	_	_
28	)	_	_	-RRB-	_	_	_	_	_
29	.	_	_	.	_	_	_	_	_


1	EMT	_	_	NNP	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	a	_	_	DT	_	_	_	_	_
4	biological	_	_	JJ	_	_	_	_	_
5	process	_	_	NN	_	_	_	_	_
6	that	_	_	WDT	_	_	_	_	_
7	polarized	_	_	VBD	_	_	_	_	_
8	epithelial	_	_	JJ	_	_	_	_	_
9	cell	_	_	NN	_	_	_	_	_
10	sheets	_	_	NNS	_	_	_	_	_
11	undergo	_	_	VBP	_	_	_	_	_
12	,	_	_	,	_	_	_	_	_
13	wherein	_	_	JJ	_	_	_	_	_
14	multiple	_	_	JJ	_	_	_	_	_
15	biochemical	_	_	JJ	_	_	_	_	_
16	changes	_	_	NNS	_	_	_	_	_
17	culminate	_	_	VBP	_	_	_	_	_
18	in	_	_	IN	_	_	_	_	_
19	mesenchymal	_	_	JJ	_	_	_	_	_
20	phenotypes	_	_	NNS	_	_	_	_	_
21	.	_	_	.	_	_	_	_	_


1	Cells	_	_	NNS	_	_	_	_	_
2	display	_	_	VBP	_	_	_	_	_
3	altered	_	_	VBN	_	_	_	_	_
4	morphology	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	resistance	_	_	NN	_	_	_	_	_
7	to	_	_	TO	_	_	_	_	_
8	chemotherapy	_	_	NN	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	and	_	_	CC	_	_	_	_	_
11	anoikis	_	_	NN	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	a	_	_	DT	_	_	_	_	_
14	form	_	_	NN	_	_	_	_	_
15	of	_	_	IN	_	_	_	_	_
16	programmed	_	_	VBN	_	_	_	_	_
17	cell	_	_	NN	_	_	_	_	_
18	death	_	_	NN	_	_	_	_	_
19	of	_	_	IN	_	_	_	_	_
20	cells	_	_	NNS	_	_	_	_	_
21	detached	_	_	VBN	_	_	_	_	_
22	from	_	_	IN	_	_	_	_	_
23	the	_	_	DT	_	_	_	_	_
24	basement	_	_	NN	_	_	_	_	_
25	membranes	_	_	NNS	_	_	_	_	_
26	)	_	_	-RRB-	_	_	_	_	_
27	.	_	_	.	_	_	_	_	_


1	EMT	_	_	NN	_	_	_	_	_
2	is	_	_	VBZ	_	_	_	_	_
3	also	_	_	RB	_	_	_	_	_
4	involved	_	_	VBN	_	_	_	_	_
5	in	_	_	IN	_	_	_	_	_
6	other	_	_	JJ	_	_	_	_	_
7	biological	_	_	JJ	_	_	_	_	_
8	processes	_	_	NNS	_	_	_	_	_
9	,	_	_	,	_	_	_	_	_
10	including	_	_	VBG	_	_	_	_	_
11	implantation	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	embryo	_	_	NN	_	_	_	_	_
14	development	_	_	NN	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	wound	_	_	NN	_	_	_	_	_
17	healing	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	tissue	_	_	NN	_	_	_	_	_
20	regeneration	_	_	NN	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	neoplasia	_	_	NN	_	_	_	_	_
24	associated	_	_	VBN	_	_	_	_	_
25	with	_	_	IN	_	_	_	_	_
26	cancer	_	_	NN	_	_	_	_	_
27	progression	_	_	NN	_	_	_	_	_
28	.	_	_	.	_	_	_	_	_


1	During	_	_	IN	_	_	_	_	_
2	invasion	_	_	NN	_	_	_	_	_
3	in	_	_	IN	_	_	_	_	_
4	cancer	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	phenotypes	_	_	NNS	_	_	_	_	_
7	also	_	_	RB	_	_	_	_	_
8	change	_	_	VBP	_	_	_	_	_
9	as	_	_	IN	_	_	_	_	_
10	EMT	_	_	NN	_	_	_	_	_
11	is	_	_	VBZ	_	_	_	_	_
12	mainly	_	_	RB	_	_	_	_	_
13	induced	_	_	VBN	_	_	_	_	_
14	by	_	_	IN	_	_	_	_	_
15	hypoxia	_	_	NN	_	_	_	_	_
16	and	_	_	CC	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	transforming	_	_	VBG	_	_	_	_	_
19	growth	_	_	NN	_	_	_	_	_
20	factor	_	_	NN	_	_	_	_	_
21	(	_	_	-LRB-	_	_	_	_	_
22	TGF)-β	_	_	NN	_	_	_	_	_
23	released	_	_	VBN	_	_	_	_	_
24	from	_	_	IN	_	_	_	_	_
25	glioma	_	_	NN	_	_	_	_	_
26	stem	_	_	NN	_	_	_	_	_
27	cells	_	_	NNS	_	_	_	_	_
28	(	_	_	-LRB-	_	_	_	_	_
29	GSCs	_	_	NNP	_	_	_	_	_
30	)	_	_	-RRB-	_	_	_	_	_
31	,	_	_	,	_	_	_	_	_
32	mesenchymal	_	_	JJ	_	_	_	_	_
33	stem	_	_	NN	_	_	_	_	_
34	cells	_	_	NNS	_	_	_	_	_
35	(	_	_	-LRB-	_	_	_	_	_
36	MSCs	_	_	NNS	_	_	_	_	_
37	)	_	_	-RRB-	_	_	_	_	_
38	,	_	_	,	_	_	_	_	_
39	and	_	_	CC	_	_	_	_	_
40	myeloid	_	_	NN	_	_	_	_	_
41	cells	_	_	NNS	_	_	_	_	_
42	recruited	_	_	VBN	_	_	_	_	_
43	by	_	_	IN	_	_	_	_	_
44	hypoxia	_	_	NN	_	_	_	_	_
45	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	reverse	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	also	_	_	RB	_	_	_	_	_
5	essential	_	_	JJ	_	_	_	_	_
6	for	_	_	IN	_	_	_	_	_
7	the	_	_	DT	_	_	_	_	_
8	formation	_	_	NN	_	_	_	_	_
9	of	_	_	IN	_	_	_	_	_
10	distant	_	_	JJ	_	_	_	_	_
11	or	_	_	CC	_	_	_	_	_
12	disseminated	_	_	VBN	_	_	_	_	_
13	tumor	_	_	NN	_	_	_	_	_
14	nodules	_	_	NNS	_	_	_	_	_
15	.	_	_	.	_	_	_	_	_


1	Stem	_	_	NN	_	_	_	_	_
2	cells	_	_	NNS	_	_	_	_	_
3	,	_	_	,	_	_	_	_	_
4	including	_	_	VBG	_	_	_	_	_
5	cancer	_	_	NN	_	_	_	_	_
6	stem	_	_	NN	_	_	_	_	_
7	cells	_	_	NNS	_	_	_	_	_
8	(	_	_	-LRB-	_	_	_	_	_
9	CSCs	_	_	NNP	_	_	_	_	_
10	)	_	_	-RRB-	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	are	_	_	VBP	_	_	_	_	_
13	pluripotent	_	_	JJ	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	capable	_	_	JJ	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	self-renewal	_	_	NN	_	_	_	_	_
18	,	_	_	,	_	_	_	_	_
19	like	_	_	IN	_	_	_	_	_
20	induced	_	_	VBN	_	_	_	_	_
21	pluripotent	_	_	JJ	_	_	_	_	_
22	stem	_	_	NN	_	_	_	_	_
23	(	_	_	-LRB-	_	_	_	_	_
24	iPS	_	_	NN	_	_	_	_	_
25	)	_	_	-RRB-	_	_	_	_	_
26	cells	_	_	NNS	_	_	_	_	_
27	induced	_	_	VBN	_	_	_	_	_
28	by	_	_	IN	_	_	_	_	_
29	the	_	_	DT	_	_	_	_	_
30	transcription	_	_	NN	_	_	_	_	_
31	factors	_	_	NNS	_	_	_	_	_
32	Oct3/4	_	_	NNP	_	_	_	_	_
33	,	_	_	,	_	_	_	_	_
34	Sox2	_	_	NNP	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	c-Myc	_	_	NNP	_	_	_	_	_
37	,	_	_	,	_	_	_	_	_
38	and	_	_	CC	_	_	_	_	_
39	Klf4	_	_	NNP	_	_	_	_	_
40	or	_	_	CC	_	_	_	_	_
41	OCT4	_	_	NNP	_	_	_	_	_
42	,	_	_	,	_	_	_	_	_
43	SOX2	_	_	NNP	_	_	_	_	_
44	,	_	_	,	_	_	_	_	_
45	NANOG	_	_	NNP	_	_	_	_	_
46	,	_	_	,	_	_	_	_	_
47	and	_	_	CC	_	_	_	_	_
48	LIN28	_	_	NNP	_	_	_	_	_
49	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	expression	_	_	NN	_	_	_	_	_
3	of	_	_	IN	_	_	_	_	_
4	OCT4	_	_	NN	_	_	_	_	_
5	,	_	_	,	_	_	_	_	_
6	MYC	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	KLF4	_	_	NNP	_	_	_	_	_
10	increases	_	_	VBZ	_	_	_	_	_
11	with	_	_	IN	_	_	_	_	_
12	increasing	_	_	VBG	_	_	_	_	_
13	malignancy	_	_	NN	_	_	_	_	_
14	in	_	_	IN	_	_	_	_	_
15	astrocytomas	_	_	NNS	_	_	_	_	_
16	,	_	_	,	_	_	_	_	_
17	whereas	_	_	IN	_	_	_	_	_
18	MYC	_	_	NN	_	_	_	_	_
19	expression	_	_	NN	_	_	_	_	_
20	slightly	_	_	RB	_	_	_	_	_
21	decreases	_	_	VBZ	_	_	_	_	_
22	in	_	_	IN	_	_	_	_	_
23	recurrent	_	_	JJ	_	_	_	_	_
24	glioblastomas	_	_	NNS	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	Exposure	_	_	NN	_	_	_	_	_
2	to	_	_	TO	_	_	_	_	_
3	temozolomide	_	_	NN	_	_	_	_	_
4	(	_	_	-LRB-	_	_	_	_	_
5	TMZ	_	_	NN	_	_	_	_	_
6	)	_	_	-RRB-	_	_	_	_	_
7	increases	_	_	VBZ	_	_	_	_	_
8	the	_	_	DT	_	_	_	_	_
9	expression	_	_	NN	_	_	_	_	_
10	of	_	_	IN	_	_	_	_	_
11	KLF4	_	_	NN	_	_	_	_	_
12	and	_	_	CC	_	_	_	_	_
13	reduces	_	_	VBZ	_	_	_	_	_
14	the	_	_	DT	_	_	_	_	_
15	expression	_	_	NN	_	_	_	_	_
16	of	_	_	IN	_	_	_	_	_
17	Nanog	_	_	NNP	_	_	_	_	_
18	and	_	_	CC	_	_	_	_	_
19	OCT4	_	_	NNP	_	_	_	_	_
20	in	_	_	IN	_	_	_	_	_
21	glioma	_	_	NN	_	_	_	_	_
22	cells	_	_	NNS	_	_	_	_	_
23	,	_	_	,	_	_	_	_	_
24	indicating	_	_	VBG	_	_	_	_	_
25	that	_	_	IN	_	_	_	_	_
26	stem	_	_	NN	_	_	_	_	_
27	cell	_	_	NN	_	_	_	_	_
28	factors	_	_	NNS	_	_	_	_	_
29	,	_	_	,	_	_	_	_	_
30	especially	_	_	RB	_	_	_	_	_
31	KLF4	_	_	NNP	_	_	_	_	_
32	,	_	_	,	_	_	_	_	_
33	play	_	_	VB	_	_	_	_	_
34	pivotal	_	_	JJ	_	_	_	_	_
35	roles	_	_	NNS	_	_	_	_	_
36	in	_	_	IN	_	_	_	_	_
37	GSCs	_	_	NNP	_	_	_	_	_
38	.	_	_	.	_	_	_	_	_


1	The	_	_	DT	_	_	_	_	_
2	most	_	_	RBS	_	_	_	_	_
3	common	_	_	JJ	_	_	_	_	_
4	GSC	_	_	NNP	_	_	_	_	_
5	marker	_	_	NN	_	_	_	_	_
6	CD133	_	_	NNP	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	also	_	_	RB	_	_	_	_	_
9	known	_	_	VBN	_	_	_	_	_
10	as	_	_	IN	_	_	_	_	_
11	prominin-1	_	_	NN	_	_	_	_	_
12	(	_	_	-LRB-	_	_	_	_	_
13	PROM1	_	_	NN	_	_	_	_	_
14	)	_	_	-RRB-	_	_	_	_	_
15	,	_	_	,	_	_	_	_	_
16	is	_	_	VBZ	_	_	_	_	_
17	used	_	_	VBN	_	_	_	_	_
18	to	_	_	TO	_	_	_	_	_
19	isolate	_	_	VB	_	_	_	_	_
20	GSCs	_	_	NNS	_	_	_	_	_
21	by	_	_	IN	_	_	_	_	_
22	fluorescence-activated	_	_	JJ	_	_	_	_	_
23	cell	_	_	NN	_	_	_	_	_
24	sorting	_	_	NN	_	_	_	_	_
25	(	_	_	-LRB-	_	_	_	_	_
26	FACS	_	_	NN	_	_	_	_	_
27	)	_	_	-RRB-	_	_	_	_	_
28	in	_	_	IN	_	_	_	_	_
29	primary	_	_	JJ	_	_	_	_	_
30	glioma	_	_	NN	_	_	_	_	_
31	tissues	_	_	NNS	_	_	_	_	_
32	and	_	_	CC	_	_	_	_	_
33	the	_	_	DT	_	_	_	_	_
34	cell	_	_	NN	_	_	_	_	_
35	lines	_	_	NNS	_	_	_	_	_
36	U87	_	_	NNP	_	_	_	_	_
37	and	_	_	CC	_	_	_	_	_
38	T98G	_	_	NNP	_	_	_	_	_
39	.	_	_	.	_	_	_	_	_


1	There	_	_	EX	_	_	_	_	_
2	are	_	_	VBP	_	_	_	_	_
3	changes	_	_	NNS	_	_	_	_	_
4	in	_	_	IN	_	_	_	_	_
5	metabolism	_	_	NN	_	_	_	_	_
6	in	_	_	IN	_	_	_	_	_
7	glioma	_	_	NN	_	_	_	_	_
8	and	_	_	CC	_	_	_	_	_
9	oxidative	_	_	JJ	_	_	_	_	_
10	phosphorylation	_	_	NN	_	_	_	_	_
11	,	_	_	,	_	_	_	_	_
12	glycolysis	_	_	NN	_	_	_	_	_
13	,	_	_	,	_	_	_	_	_
14	and	_	_	CC	_	_	_	_	_
15	glutaminolysis	_	_	NN	_	_	_	_	_
16	replace	_	_	VBP	_	_	_	_	_
17	redox	_	_	NN	_	_	_	_	_
18	balance	_	_	NN	_	_	_	_	_
19	,	_	_	,	_	_	_	_	_
20	bioenergetics	_	_	NNS	_	_	_	_	_
21	,	_	_	,	_	_	_	_	_
22	and	_	_	CC	_	_	_	_	_
23	biosynthesis	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	respectively	_	_	RB	_	_	_	_	_
26	.	_	_	.	_	_	_	_	_


1	Tumor	_	_	NN	_	_	_	_	_
2	progression	_	_	NN	_	_	_	_	_
3	is	_	_	VBZ	_	_	_	_	_
4	enhanced	_	_	VBN	_	_	_	_	_
5	by	_	_	IN	_	_	_	_	_
6	inflammation	_	_	NN	_	_	_	_	_
7	,	_	_	,	_	_	_	_	_
8	which	_	_	WDT	_	_	_	_	_
9	is	_	_	VBZ	_	_	_	_	_
10	an	_	_	DT	_	_	_	_	_
11	emerging	_	_	JJ	_	_	_	_	_
12	hallmark	_	_	NN	_	_	_	_	_
13	of	_	_	IN	_	_	_	_	_
14	cancers	_	_	NNS	_	_	_	_	_
15	that	_	_	WDT	_	_	_	_	_
16	depends	_	_	VBZ	_	_	_	_	_
17	on	_	_	IN	_	_	_	_	_
18	the	_	_	DT	_	_	_	_	_
19	balance	_	_	NN	_	_	_	_	_
20	of	_	_	IN	_	_	_	_	_
21	glioma	_	_	NN	_	_	_	_	_
22	cell	_	_	NN	_	_	_	_	_
23	proliferation	_	_	NN	_	_	_	_	_
24	,	_	_	,	_	_	_	_	_
25	migration	_	_	NN	_	_	_	_	_
26	,	_	_	,	_	_	_	_	_
27	and	_	_	CC	_	_	_	_	_
28	escape	_	_	VBP	_	_	_	_	_
29	from	_	_	IN	_	_	_	_	_
30	the	_	_	DT	_	_	_	_	_
31	immune	_	_	JJ	_	_	_	_	_
32	system	_	_	NN	_	_	_	_	_
33	.	_	_	.	_	_	_	_	_


1	However	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	correlation	_	_	NN	_	_	_	_	_
5	between	_	_	IN	_	_	_	_	_
6	EMT	_	_	NNP	_	_	_	_	_
7	and	_	_	CC	_	_	_	_	_
8	GSCs	_	_	NNS	_	_	_	_	_
9	in	_	_	IN	_	_	_	_	_
10	glioblastoma	_	_	NN	_	_	_	_	_
11	has	_	_	VBZ	_	_	_	_	_
12	not	_	_	RB	_	_	_	_	_
13	been	_	_	VBN	_	_	_	_	_
14	reported	_	_	VBN	_	_	_	_	_
15	to	_	_	TO	_	_	_	_	_
16	date	_	_	NN	_	_	_	_	_
17	.	_	_	.	_	_	_	_	_


1	In	_	_	IN	_	_	_	_	_
2	this	_	_	DT	_	_	_	_	_
3	study	_	_	NN	_	_	_	_	_
4	,	_	_	,	_	_	_	_	_
5	we	_	_	PRP	_	_	_	_	_
6	focused	_	_	VBD	_	_	_	_	_
7	on	_	_	IN	_	_	_	_	_
8	EMT	_	_	NNP	_	_	_	_	_
9	and	_	_	CC	_	_	_	_	_
10	GSCs	_	_	NNP	_	_	_	_	_
11	and	_	_	CC	_	_	_	_	_
12	performed	_	_	VBD	_	_	_	_	_
13	multivariable	_	_	JJ	_	_	_	_	_
14	analyses	_	_	NNS	_	_	_	_	_
15	using	_	_	VBG	_	_	_	_	_
16	the	_	_	DT	_	_	_	_	_
17	expression	_	_	NN	_	_	_	_	_
18	data	_	_	NNS	_	_	_	_	_
19	and	_	_	CC	_	_	_	_	_
20	OS	_	_	NN	_	_	_	_	_
21	in	_	_	IN	_	_	_	_	_
22	patients	_	_	NNS	_	_	_	_	_
23	with	_	_	IN	_	_	_	_	_
24	glioblastoma	_	_	NN	_	_	_	_	_
25	.	_	_	.	_	_	_	_	_


1	To	_	_	TO	_	_	_	_	_
2	determine	_	_	VB	_	_	_	_	_
3	the	_	_	DT	_	_	_	_	_
4	distribution	_	_	NN	_	_	_	_	_
5	of	_	_	IN	_	_	_	_	_
6	survival	_	_	NN	_	_	_	_	_
7	of	_	_	IN	_	_	_	_	_
8	glioblastoma	_	_	NN	_	_	_	_	_
9	patients	_	_	NNS	_	_	_	_	_
10	,	_	_	,	_	_	_	_	_
11	we	_	_	PRP	_	_	_	_	_
12	composed	_	_	VBD	_	_	_	_	_
13	prognosis	_	_	NN	_	_	_	_	_
14	prediction	_	_	NN	_	_	_	_	_
15	formulae	_	_	NNS	_	_	_	_	_
16	for	_	_	IN	_	_	_	_	_
17	the	_	_	DT	_	_	_	_	_
18	following	_	_	VBG	_	_	_	_	_
19	components	_	_	NNS	_	_	_	_	_
20	:	_	_	:	_	_	_	_	_
21	epithelium	_	_	NN	_	_	_	_	_
22	(	_	_	-LRB-	_	_	_	_	_
23	EPI	_	_	NN	_	_	_	_	_
24	)	_	_	-RRB-	_	_	_	_	_
25	,	_	_	,	_	_	_	_	_
26	mesenchyme	_	_	NN	_	_	_	_	_
27	(	_	_	-LRB-	_	_	_	_	_
28	MES	_	_	NN	_	_	_	_	_
29	)	_	_	-RRB-	_	_	_	_	_
30	,	_	_	,	_	_	_	_	_
31	glioma	_	_	NN	_	_	_	_	_
32	(	_	_	-LRB-	_	_	_	_	_
33	GLI	_	_	NN	_	_	_	_	_
34	)	_	_	-RRB-	_	_	_	_	_
35	,	_	_	,	_	_	_	_	_
36	GSC	_	_	NN	_	_	_	_	_
37	,	_	_	,	_	_	_	_	_
38	molecular	_	_	JJ	_	_	_	_	_
39	target	_	_	NN	_	_	_	_	_
40	therapy	_	_	NN	_	_	_	_	_
41	(	_	_	-LRB-	_	_	_	_	_
42	MTT	_	_	NN	_	_	_	_	_
43	)	_	_	-RRB-	_	_	_	_	_
44	genes	_	_	NNS	_	_	_	_	_
45	,	_	_	,	_	_	_	_	_
46	and	_	_	CC	_	_	_	_	_
47	potential	_	_	JJ	_	_	_	_	_
48	glioma	_	_	NN	_	_	_	_	_
49	biomarkers	_	_	NNS	_	_	_	_	_
50	(	_	_	-LRB-	_	_	_	_	_
51	PGBs	_	_	NNP	_	_	_	_	_
52	)	_	_	-RRB-	_	_	_	_	_
53	.	_	_	.	_	_	_	_	_


1	Consequently	_	_	RB	_	_	_	_	_
2	,	_	_	,	_	_	_	_	_
3	several	_	_	JJ	_	_	_	_	_
4	candidate	_	_	NN	_	_	_	_	_
5	genes	_	_	NNS	_	_	_	_	_
6	were	_	_	VBD	_	_	_	_	_
7	identified	_	_	VBN	_	_	_	_	_
8	as	_	_	IN	_	_	_	_	_
9	promising	_	_	JJ	_	_	_	_	_
10	glioblastoma	_	_	NN	_	_	_	_	_
11	predictors	_	_	NNS	_	_	_	_	_
12	.	_	_	.	_	_	_	_	_

